Subscribe

Neutra Corp. (NTRR)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address 54 Sugar Creek Center Boulevard 77478
Houston, TX, US
CEO Sydney Jim
Website neutrainc.com
IPO 2011-10-12
CIK 1512886 ISIN US64129C3034

Explore sections of this company profile

Description

Neutra Corp. specializes in the research, development, and provision of hemp-derived nutraceuticals. Its product portfolio features items such as CBD-infused sports creams, in addition to a variety of other health and wellness goods. Established in 2011, the company is headquartered in Sugar Land, Texas.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.48
Float Shares
2.90B
Free Float %
99.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-33.33% -33.33% +0.00% +0.00% -50.00% +0.00% +9,900.00% -75.00% -97.37% -99.99% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
15.19
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +1,403.9% ★ Q1'26: +20,931.0% (vs Q1'25)
  • ✓
    EPS growth Biotechnology: +29.7%
    —
  • ✓
    FCF margin FCF growth · Biotechnology: +16.2%
    +12.6% Q1'26: +1.3% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    +8.6% ★ Q1'26: +418.5% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: -2,076.1% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +0.1% ★ Q1'26: +4.3% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    1.24× Q1'26: 0.03× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.48) × ERP
WACC = 72% × Ke + 28% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-27 C- 1/5 1/5 3/5 1/5 1/5 1/5 1/5
2026-05-21 C- 1/5 1/5 3/5 1/5 1/5 1/5 1/5
2026-05-19 C- 1/5 1/5 3/5 1/5 1/5 1/5 1/5
2026-05-15 C- 1/5 1/5 3/5 1/5 1/5 1/5 1/5
2026-05-14 C- 1/5 1/5 3/5 1/5 1/5 1/5 1/5
2026-05-13 C- 1/5 1/5 3/5 1/5 1/5 1/5 1/5
2026-05-11 C- 1/5 1/5 3/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-05-01 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 2/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
298.8K
OE per share TTM
0.00
Owner's Yield
98.18%
Maintenance CapEx ratio
4.64%
Maint CapEx / Avg PPE
27.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 35-2553872 622.0K 9.99% 622.0K — 622.0K — OO NEW YORK 2018-01-16 ↗
2 46-4896047 187.4K 9.99% 187.4K — 187.4K — OO NEW YORK 2016-09-01 ↗

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
5.8K
Shares Outstanding
2.92B

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2015 Cindy Morrissey, Former CEO and Chairman of the Board 105.0K — — — — — 105.0K 0.00% ↗
2 2014 Christopher Brown CEO and Chairman of the Board 31.2K — — — — — 31.2K 0.00% ↗
3 2014 Michael-Shane Henderson, Former CEO and Chairman of the Board 30.0K — — — — — 30.0K 0.00% ↗
4 2013 Sydney Jim Former CEO and Chairman of the Board 65.0K — — — — — 65.0K 0.00% ↗
5 2013 Michael-Shane Henderson, Former CEO and Chairman of the Board 62.5K — — — — — 62.5K 0.00% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2024-12-12 15-12G ↗
2024-08-07 10-Q ↗
2024-08-02 10-K ↗
2024-06-17 NT 10-Q ↗
2024-05-15 8-K ↗
2024-04-30 NT 10-K ↗
2023-12-15 10-Q ↗
2023-09-14 10-Q ↗
2023-08-04 8-K ↗
2023-06-22 10-Q ↗

Executive team

NameTitleCompensationGender
Sydney Jim Chief Executive Officer, President, Secretary, Treasurer, Principal Finance & Accounting Officer and Sole Director 100.0K male
ESG Rating
B
BIOTECHNOLOGY
2024
E (Environmental)
56.9 / 56.3
Company / Sector avg.
S (Social)
63.6 / 62.4
Company / Sector avg.
G (Governance)
55.4 / 60.9
Company / Sector avg.
ESG Total
58.6 / 59.9
Company / Sector avg.
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology